

# Ricardo C T Aguiar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6602566/publications.pdf>

Version: 2024-02-01

28  
papers

4,536  
citations

361413

20  
h-index

501196

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

6088  
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC, mitochondrial metabolism and O-GlcNAcylation converge to modulate the activity and subcellular localization of DNA and RNA demethylases. <i>Leukemia</i> , 2022, 36, 1150-1159.	7.2	8
2	Cyclic AMP signalling, MYC and hypoxia-inducible factor 1 intersect to regulate angiogenesis in B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, , .	2.5	2
3	Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression. <i>Leukemia</i> , 2021, 35, 1990-2001.	7.2	15
4	Generation and characterization of the Eμ-Irf8 mouse model. <i>Cancer Genetics</i> , 2020, 245, 6-16.	0.4	5
5	MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. <i>Cell Chemical Biology</i> , 2020, 27, 538-550.e7.	5.2	14
6	The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner. <i>Nature Communications</i> , 2019, 10, 4720.	12.8	14
7	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K $\gamma$ in Mature B-cell Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 1103-1113.	7.0	18
8	IDH Mutation, Competitive Inhibition of FTO, and RNA Methylation. <i>Cancer Cell</i> , 2017, 31, 619-620.	16.8	65
9	Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma. <i>Trends in Cancer</i> , 2017, 3, 871-882.	7.4	8
10	Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 1186-1192.	7.0	25
11	Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. <i>Oncotarget</i> , 2017, 8, 14912-14924.	1.8	24
12	Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies. <i>Blood</i> , 2016, 128, 2886-2890.	1.4	20
13	Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. <i>Clinical Cancer Research</i> , 2016, 22, 2301-2310.	7.0	136
14	A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma. <i>Leukemia</i> , 2016, 30, 617-626.	7.2	48
15	MicroRNA 155 Control of p53 Activity Is Context Dependent and Mediated by Aicda and Socs1. <i>Molecular and Cellular Biology</i> , 2015, 35, 1329-1340.	2.3	54
16	D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. <i>Nature Communications</i> , 2015, 6, 7768.	12.8	64
17	MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF- $\beta$ 1/SMAD5 signaling module. <i>Blood</i> , 2014, 123, 86-93.	1.4	42
18	A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. <i>Blood</i> , 2013, 122, 726-733.	1.4	44

#	ARTICLE	IF	CITATIONS
19	MicroRNAs miR-125a and miR-125b constitutively activate the NF- $\kappa$ B pathway by targeting the tumor necrosis factor alpha-induced protein 3 ( <i>TNFAIP3</i> ). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7865-7870.	7.1	305
20	Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma. Clinical Cancer Research, 2011, 17, 6723-6732.	7.0	34
21	Targeting of SMAD5 links microRNA-155 to the TGF- $\beta$ 2 pathway and lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3111-3116.	7.1	198
22	MicroRNA-155 expression and outcome in diffuse large B-cell lymphoma. British Journal of Haematology, 2009, 144, 138-140.	2.5	31
23	Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma. Blood, 2009, 113, 6681-6690.	1.4	71
24	Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood, 2009, 113, 6153-6160.	1.4	37
25	The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood, 2005, 105, 308-316.	1.4	141
26	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	1.4	778
27	Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood, 2003, 102, 4187-4190.	1.4	118
28	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Medicine, 2002, 8, 68-74.	30.7	2,217